Rezultati pretrage - WEISE, AMY
- Prikaz rezultata 1 – 19 od 19
-
1
-
2
-
3
-
4
Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination od Gibson, Heather, Veenstra, Jesse, Jones, Richard, Vaishampayan, Ulka, Sauerbrey, Michele, Bepler, Gerold, Lum, Lawrence, Reyes, Joyce, Weise, Amy, Wei, Wei-Zen
Izdano 2015Tekst -
5
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression od Fu, Jiaqi, Weise, Amy M., Falany, Josie L., Falany, Charles N., Thibodeau, Bryan J., Miller, Fred R., Kocarek, Thomas A., Runge-Morris, Melissa
Izdano 2009Tekst -
6
Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity od Jacob, Jennifer B., Quaglino, Elena, Radkevich-Brown, Olga, Jones, Richard F., Piechocki, Marie P., Reyes, Joyce D., Weise, Amy, Amici, Augusto, Wei, Wei-Zen
Izdano 2010Tekst -
7
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution od SUKARI, AMMAR, NAGASAKA, MISAKO, ALHASAN, ROBA, PATEL, DHAVAL, WOZNIAK, ANTOINETTE, RAMCHANDREN, RADHAKRISHNAN, VAISHAMPAYAN, ULKA, WEISE, AMY, FLAHERTY, LAWRENCE, JANG, HYEJEONG, KIM, SEONGHO, GADGEEL, SHIRISH
Izdano 2019Tekst -
8
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer od Bardia, Aditya, Kaklamani, Virginia, Wilks, Sharon, Weise, Amy, Richards, Donald, Harb, Wael, Osborne, Cynthia, Wesolowski, Robert, Karuturi, Meghan, Conkling, Paul, Bagley, Rebecca G., Wang, Yamei, Conlan, Maureen G., Kabos, Peter
Izdano 2021Tekst -
9
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors od Rosen, Lee S., LoRusso, Patricia, Ma, Wen Wee, Goldman, Jonathan W., Weise, Amy, Colevas, A. Dimitrios, Adjei, Alex, Yazji, Salim, Shen, Angela, Johnston, Stuart, Hsieh, Hsin-Ju, Chan, Iris T., Sikic, Branimir I.
Izdano 2016Tekst -
10
Phase I Study Combining the Aurora Kinase A Inhibitor Alisertib with mFOLFOX in Gastrointestinal Cancer od Goff, Laura W., Azad, Nilofer S., Stein, Stacey, Whisenant, Jennifer G., Koyama, Tatsuki, Vaishampayan, Ulka, Hochster, Howard, Connolly, Roisin, Weise, Amy, LoRusso, Patricia M., Salaria, Safia N., El-Rifai, Wael, Berlin, Jordan D.
Izdano 2018Tekst -
11
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases od In, Gino K., Poorman, Kelsey, Saul, Michelle, O’Day, Steven, Farma, Jeffrey M., Olszanski, Anthony J., Gordon, Michael S., Thomas, Jacob S., Eisenberg, Burton, Flaherty, Lawrence, Weise, Amy, Daveluy, Steven, Gibney, Geoffrey, Atkins, Michael B., Vanderwalde, Ari
Izdano 2020Tekst -
12
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer od Tsimberidou, Apostolia-Maria, Shaw, Jamie V., Juric, Dejan, Verschraegen, Claire, Weise, Amy M., Sarantopoulos, John, Lopes, Gilberto, Nemunaitis, John, Mita, Monica, Park, Haeseong, Ellers-Lenz, Barbara, Tian, Hui, Xiong, Wenyuan, Kaleta, Remigiusz, Kurzrock, Razelle
Izdano 2021Tekst -
13
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors od Garrido-Laguna, Ignacio, Krop, Ian, Burris, Howard A., Hamilton, Erika, Braiteh, Fadi, Weise, Amy M., Abu-Khalaf, Maysa, Werner, Theresa L., Pirie-Shepherd, Steven, Zopf, Christopher J., Lakshminarayanan, Mani, Holland, Jaymes S., Baffa, Raffaele, Hong, David S.
Izdano 2019Tekst -
14
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR(+), HER2(−) Advanced Breast Cancer od Bardia, Aditya, Modi, Shanu, Oliveira, Mafalda, Cortes, Javier, Campone, Mario, Ma, Brigette, Dirix, Luc, Weise, Amy, Hewes, Becker, Diaz-Padilla, Ivan, Han, Yu, Deshpande, Priya, Samant, Tanay S., Rodriguez Lorenc, Karen, He, Wei, Su, Fei, Chavez-MacGregor, Mariana
Izdano 2020Tekst -
15
First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors od Do, Khanh T., Chow, Laura Quan Man, Reckamp, Karen, Sanborn, Rachel E., Burris, Howard, Robert, Francisco, Camidge, D. Ross, Steuer, Conor E., Strickler, John H., Weise, Amy, Specht, Jennifer M., Gutierrez, Martin, Haughney, Peter, Hengel, Shawna, Derleth, Christina Louise, Yap, Timothy A.
Izdano 2021Tekst -
16
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies od Naing, Aung, Infante, Jeffrey, Goel, Sanjay, Burris, Howard, Black, Chelsea, Marshall, Shannon, Achour, Ikbel, Barbee, Susannah, May, Rena, Morehouse, Chris, Pollizzi, Kristen, Song, Xuyang, Steele, Keith, Elgeioushi, Nairouz, Walcott, Farzana, Karakunnel, Joyson, LoRusso, Patricia, Weise, Amy, Eder, Joseph, Curti, Brendan, Oberst, Michael
Izdano 2019Tekst -
17
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma od Shapiro, Geoffrey I., LoRusso, Patricia, Dowlati, Afshin, T. Do, Khanh, Jacobson, Caron A., Vaishampayan, Ulka, Weise, Amy, Caimi, Paolo F., Eder, Joseph Paul, French, Christopher A., Labriola-Tompkins, Emily, Boisserie, Frédéric, Pierceall, William E., Zhi, Jianguo, Passe, Sharon, DeMario, Mark, Kornacker, Martin, Armand, Philippe
Izdano 2020Tekst -
18
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer od Fong, Lawrence, Hotson, Andrew, Powderly, John D., Sznol, Mario, Heist, Rebecca S., Choueiri, Toni K., George, Saby, Hughes, Brett G.M., Hellmann, Matthew D., Shepard, Dale R., Rini, Brian I., Kummar, Shivaani, Weise, Amy M., Riese, Matthew J., Markman, Ben, Emens, Leisha A., Mahadevan, Daruka, Luke, Jason J., Laport, Ginna, Brody, Joshua D., Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W., Berim, Lyudmyla, Renouf, Daniel J., Goodwin, Rachel A., Munneke, Brian, Ho, Po Y., Hsieh, Jessica, McCaffery, Ian, Kwei, Long, Willingham, Stephen B., Miller, Richard A.
Izdano 2019Tekst -
19
Identifying treatment options for BRAF(V600) wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial od LoRusso, Patricia M., Sekulic, Aleksandar, Sosman, Jeffrey A., Liang, Winnie S., Carpten, John, Craig, David W., Solit, David B., Bryce, Alan H., Kiefer, Jeffrey A., Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A., Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane, Hendricks, William P. D., Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N., Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D., Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S., Petricoin, Emanuel F., Fecher, Leslie Anne, Lao, Christopher, Eder, J. Paul, Vogelzang, Nicholas J., Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W., Cowey, C. Lance, Trent, Jeffrey M.
Izdano 2021Tekst